Valuation Update With 7 Day Price Move • May 08
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₩291,500, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 20x in the Biotechs industry in South Korea. Total returns to shareholders of 161% over the past three years. Annonce • May 01
Hugel, Inc. to Report Q1, 2026 Results on May 07, 2026 Hugel, Inc. announced that they will report Q1, 2026 results on May 07, 2026 Reported Earnings • Mar 25
Full year 2025 earnings: EPS and revenues exceed analyst expectations Full year 2025 results: EPS: ₩13,061 (up from ₩12,520 in FY 2024). Revenue: ₩425.1b (up 14% from FY 2024). Net income: ₩140.9b (up 3.7% from FY 2024). Profit margin: 33% (down from 36% in FY 2024). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 1.1%. Earnings per share (EPS) also surpassed analyst estimates by 9.8%. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in South Korea. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has only increased by 28% per year, which means it is significantly lagging earnings growth. Annonce • Mar 17
Hugel, Inc., Annual General Meeting, Mar 31, 2026 Hugel, Inc., Annual General Meeting, Mar 31, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 31, bonguisan-gil, gangwon-do, chuncheon South Korea Reported Earnings • Feb 12
Full year 2025 earnings released: EPS: ₩12,776 (vs ₩12,520 in FY 2024) Full year 2025 results: EPS: ₩12,776 (up from ₩12,520 in FY 2024). Revenue: ₩425.1b (up 14% from FY 2024). Net income: ₩138.0b (up 1.6% from FY 2024). Profit margin: 33% (down from 36% in FY 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 28% growth forecast for the Biotechs industry in South Korea. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has only increased by 24% per year, which means it is significantly lagging earnings growth. Annonce • Feb 04
Hugel, Inc. to Report Q4, 2025 Results on Feb 11, 2026 Hugel, Inc. announced that they will report Q4, 2025 results on Feb 11, 2026 Valuation Update With 7 Day Price Move • Jan 26
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to ₩285,500, the stock trades at a forward P/E ratio of 20x. Average forward P/E is 18x in the Biotechs industry in South Korea. Total returns to shareholders of 101% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩422,247 per share. Price Target Changed • Nov 07
Price target decreased by 10% to ₩389,000 Down from ₩433,667, the current price target is an average from 15 analysts. New target price is 82% above last closing price of ₩214,000. Stock is down 28% over the past year. The company is forecast to post earnings per share of ₩11,775 for next year compared to ₩12,520 last year. Valuation Update With 7 Day Price Move • Nov 06
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to ₩217,500, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 19x in the Biotechs industry in South Korea. Total returns to shareholders of 82% over the past three years. Annonce • Oct 31
Hugel, Inc. to Report Nine Months, 2025 Results on Nov 04, 2025 Hugel, Inc. announced that they will report nine months, 2025 results on Nov 04, 2025 Annonce • Aug 12
Hugel Inc. Launches Botulinum Toxin Letybo in Malaysia Hugel Inc. has officially launched its botulinum toxin product Letybo in Malaysia - an emerging market for medical aesthetics in Southeast Asia. The company's Malaysian partner Venusys Medical Sdn Bhd introduced Letybo at the Aesthetic Medicine & Surgery Conference & Exhibition (AMSC), the largest medical aesthetics conference in Malaysia, held from August 6 to 7. Konstantin Frank, a key opinion leader for Letybo in Europe, delivered a presentation at the event, highlighting the precise treatment outcomes of botulinum toxin procedures and sharing clinical strategies to enhance procedure results. A brand launch event and hands-on workshop followed on August 8 at The Zenith Hotel Kuantan, with around 100 local medical professionals in attendance. The workshop served as a training program focused on botulinum toxin injection techniques that integrate anatomical understanding with clinical expertise. Annonce • Jul 30
Hugel, Inc. to Report Q2, 2025 Results on Aug 06, 2025 Hugel, Inc. announced that they will report Q2, 2025 results on Aug 06, 2025 Buy Or Sell Opportunity • Jun 13
Now 20% undervalued Over the last 90 days, the stock has risen 7.9% to ₩356,000. The fair value is estimated to be ₩446,977, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has grown by 39%. Revenue is forecast to grow by 47% in 2 years. Earnings are forecast to grow by 60% in the next 2 years. Valuation Update With 7 Day Price Move • Jun 12
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₩376,500, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 33x in the Biotechs industry in South Korea. Total returns to shareholders of 243% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩446,977 per share. Buy Or Sell Opportunity • May 28
Now 27% undervalued after recent price drop Over the last 90 days, the stock has fallen 1.5% to ₩324,500. The fair value is estimated to be ₩446,977, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has grown by 39%. Revenue is forecast to grow by 46% in 2 years. Earnings are forecast to grow by 58% in the next 2 years. Annonce • May 02
Hugel, Inc. to Report Q1, 2025 Results on May 08, 2025 Hugel, Inc. announced that they will report Q1, 2025 results on May 08, 2025 Reported Earnings • Mar 26
Full year 2024 earnings: EPS exceeds analyst expectations Full year 2024 results: EPS: ₩12,520 (up from ₩8,217 in FY 2023). Revenue: ₩373.0b (up 17% from FY 2023). Net income: ₩135.8b (up 46% from FY 2023). Profit margin: 36% (up from 29% in FY 2023). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 10%. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 31% growth forecast for the Biotechs industry in South Korea. Over the last 3 years on average, earnings per share has increased by 36% per year whereas the company’s share price has increased by 34% per year. Annonce • Mar 18
Hugel, Inc., Annual General Meeting, Mar 31, 2025 Hugel, Inc., Annual General Meeting, Mar 31, 2025, at 09:00 Tokyo Standard Time. Location: sapphire hall, 31, bonguisan-gil, gangwon-do, chuncheon South Korea Annonce • Feb 07
Hugel, Inc. to Report Fiscal Year 2024 Results on Feb 13, 2025 Hugel, Inc. announced that they will report fiscal year 2024 results on Feb 13, 2025 Annonce • Dec 05
Hugel, Inc. (KOSDAQ:A145020) announces an Equity Buyback for KRW 70,000 million worth of its shares. Hugel, Inc. (KOSDAQ:A145020) announces a share repurchase program. Under the program, the company will repurchase up to KRW 70,000 million worth of its shares pursuant to a contract with NH Investment & Securities Co., Ltd. The purpose of the buyback is to enhance shareholder value inventory and stock price stability. The plan will be valid up to June 4, 2025. As of December 4, 2024, the company had 1,588,910 shares within scope available for dividend and 2,341 shares in treasury through other repurchase. Price Target Changed • Nov 09
Price target increased by 7.3% to ₩352,545 Up from ₩328,636, the current price target is an average from 11 analysts. New target price is 19% above last closing price of ₩296,000. Stock is up 118% over the past year. The company is forecast to post earnings per share of ₩10,672 for next year compared to ₩8,217 last year. Valuation Update With 7 Day Price Move • Nov 06
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₩321,000, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 23x in the Biotechs industry in South Korea. Total returns to shareholders of 120% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩470,081 per share. Annonce • Oct 30
Hugel, Inc. to Report Q3, 2024 Results on Nov 06, 2024 Hugel, Inc. announced that they will report Q3, 2024 results on Nov 06, 2024 Valuation Update With 7 Day Price Move • Oct 17
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₩281,000, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 24x in the Biotechs industry in South Korea. Total returns to shareholders of 58% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩440,659 per share. Major Estimate Revision • Aug 09
Consensus EPS estimates increase by 13% The consensus outlook for fiscal year 2024 has been updated. 2024 EPS estimate increased from ₩8,509 to ₩9,585. Revenue forecast steady at ₩369.9m. Net income forecast to grow 21% next year vs 27% growth forecast for Biotechs industry in South Korea. Consensus price target up from ₩260,556 to ₩285,000. Share price rose 11% to ₩261,500 over the past week. Price Target Changed • Aug 09
Price target increased by 7.2% to ₩279,444 Up from ₩260,556, the current price target is an average from 9 analysts. New target price is 7.9% above last closing price of ₩259,000. Stock is up 125% over the past year. The company is forecast to post earnings per share of ₩9,585 for next year compared to ₩8,217 last year. Valuation Update With 7 Day Price Move • Aug 05
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ₩211,000, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 26x in the Biotechs industry in South Korea. Total loss to shareholders of 9.8% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩280,601 per share. Buy Or Sell Opportunity • Aug 05
Now 25% undervalued Over the last 90 days, the stock has risen 6.2% to ₩211,000. The fair value is estimated to be ₩280,601, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 22%. Revenue is forecast to grow by 36% in 2 years. Earnings are forecast to grow by 43% in the next 2 years. Annonce • Aug 04
Hugel, Inc. to Report Q2, 2024 Results on Aug 07, 2024 Hugel, Inc. announced that they will report Q2, 2024 results on Aug 07, 2024 Price Target Changed • Jun 13
Price target increased by 13% to ₩254,889 Up from ₩224,889, the current price target is an average from 9 analysts. New target price is 6.9% above last closing price of ₩238,500. Stock is up 135% over the past year. The company is forecast to post earnings per share of ₩8,509 for next year compared to ₩8,217 last year. Valuation Update With 7 Day Price Move • Jun 11
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to ₩242,000, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 24x in the Biotechs industry in South Korea. Total loss to shareholders of 2.4% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩247,776 per share. Buy Or Sell Opportunity • May 30
Now 21% undervalued Over the last 90 days, the stock has risen 4.6% to ₩192,300. The fair value is estimated to be ₩243,082, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 22%. Revenue is forecast to grow by 36% in 2 years. Earnings are forecast to grow by 43% in the next 2 years. Buy Or Sell Opportunity • May 11
Now 22% undervalued Over the last 90 days, the stock has risen 35% to ₩201,500. The fair value is estimated to be ₩257,244, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 20%. For the next 3 years, revenue is forecast to grow by 14% per annum. Earnings are also forecast to grow by 18% per annum over the same time period. Annonce • May 03
Hugel, Inc. to Report Q1, 2024 Final Results on May 09, 2024 Hugel, Inc. announced that they will report Q1, 2024 final results on May 09, 2024 Annonce • Mar 27
Hugel, Inc. (KOSDAQ:A145020) announces an Equity Buyback for KRW 50,000 million worth of its shares. Hugel, Inc. (KOSDAQ:A145020) announces a share repurchase program. Under the program, the company will repurchase up to KRW 50,000 million worth of its shares pursuant to a contract with NH Investment & Securities Co., Ltd. The purpose of the buyback is to enhance shareholder value inventory and stock price stability. The plan will be valid up to September 27, 2024. As of March 26, 2024, the company had 1,384,910 shares within scope available for dividend and 2,341 shares in treasury through other repurchase. Buy Or Sell Opportunity • Mar 19
Now 23% undervalued Over the last 90 days, the stock has risen 24% to ₩181,000. The fair value is estimated to be ₩236,000, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 18%. Revenue is forecast to grow by 37% in 2 years. Earnings are forecast to grow by 61% in the next 2 years. Valuation Update With 7 Day Price Move • Feb 20
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₩181,400, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 19x in the Biotechs industry in South Korea. Negligible returns to shareholders over past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩218,112 per share. Price Target Changed • Feb 16
Price target increased by 8.7% to ₩201,750 Up from ₩185,625, the current price target is an average from 8 analysts. New target price is 20% above last closing price of ₩168,800. Stock is up 26% over the past year. The company is forecast to post earnings per share of ₩7,840 for next year compared to ₩5,082 last year. Annonce • Feb 13
Hugel, Inc. (KOSDAQ:A145020) announces an Equity Buyback for KRW 50,000 million worth of its shares. Hugel, Inc. (KOSDAQ:A145020) announces a share repurchase program. Under the program, the company will repurchase up to KRW 50,000 million worth of its shares pursuant to a contract with NH Investment & Securities Co., Ltd. The purpose of the buyback is to stabilize the share price and enhance the shareholder's value. The plan will be valid up to August 14, 2024. As on February 12, 2024, the company had 1,124,910 shares within scope available for dividend and 2,341 shares in treasury through other repurchase. Major Estimate Revision • Nov 16
Consensus EPS estimates increase by 38% The consensus outlook for earnings per share (EPS) in fiscal year 2023 has improved. 2023 revenue forecast increased from ₩319.2m to ₩329.3m. EPS estimate increased from ₩6,465 to ₩8,894 per share. Net income forecast to grow 54% next year vs 31% growth forecast for Biotechs industry in South Korea. Consensus price target up from ₩161,143 to ₩172,571. Share price rose 8.2% to ₩147,700 over the past week. Price Target Changed • Nov 15
Price target increased by 8.1% to ₩172,571 Up from ₩159,714, the current price target is an average from 7 analysts. New target price is 16% above last closing price of ₩148,700. Stock is up 29% over the past year. The company is forecast to post earnings per share of ₩7,031 for next year compared to ₩5,082 last year. Annonce • Sep 02
Hugel Resubmits BLA for Its Botulinum Toxin, Letybo to the U.S. Fda Hugel announced that the company resubmitted the BLA for its botulinum toxin, Letybo (letibotulinumtoxinA) on August 31st (local time), for the indication of glabellar (frown) lines to the U.S. FDA. Hugel had received a Complete Response Letter (CRL) from the U.S. FDA earlier this year after submitting the BLA for Letybo in October 2022. The company has resubmitted the BLA after completing a review of the facility management and supplementary work in-line with the CRL requests received from the FDA. As it takes around six months to obtain marketing approval from the period of a BLA submission, marketing approval for Letybo is projected for the first quarter of 2024. Letybo is the No.1 product in the Korean botulinum toxin market and has successfully entered global markets such as China, Europe, and Australia, becoming the first Korean toxin brand to be launched. Hugel also received approval for Letybo in Canada in June of last year and is preparing for commercial launch within the year. Price Target Changed • Aug 24
Price target decreased by 8.8% to ₩159,250 Down from ₩174,625, the current price target is an average from 8 analysts. New target price is 36% above last closing price of ₩117,400. Stock is down 5.8% over the past year. The company is forecast to post earnings per share of ₩6,211 for next year compared to ₩5,082 last year. Annonce • May 06
Hugel, Inc. (KOSDAQ:A145020) acquired additional 3.13% stake in Across Co., Ltd for KRW 9.385 billion. Hugel, Inc. (KOSDAQ:A145020) acquired additional 3.13% stake in Across Co., Ltd. for KRW 9.385 billion on May 4, 2023.
Hugel, Inc. (KOSDAQ:A145020) completed the acquisition of an additional 3.13% stake in Across Co., Ltd. on May 4, 2023. Valuation Update With 7 Day Price Move • Apr 20
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to ₩110,700, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 24x in the Biotechs industry in South Korea. Total loss to shareholders of 16% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩116,417 per share. Price Target Changed • Mar 23
Price target increased by 7.3% to ₩189,714 Up from ₩176,750, the current price target is an average from 7 analysts. New target price is 48% above last closing price of ₩128,100. Stock is down 10% over the past year. The company is forecast to post earnings per share of ₩5,843 for next year compared to ₩4,733 last year. Valuation Update With 7 Day Price Move • Feb 16
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to ₩134,300, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 25x in the Biotechs industry in South Korea. Negligible returns to shareholders over past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩256,831 per share. Annonce • Feb 15
Hugel, Inc. (KOSDAQ:A145020) announces an Equity Buyback for KRW 50,000 million worth of its shares. Hugel, Inc. (KOSDAQ:A145020) announces a share repurchase program. Under the program, the company will repurchase up to KRW 50,000 million worth of its shares pursuant to a contract with NH Investment & Securities. The purpose of the buyback is to stabilize the share price and enhance the shareholder's value. The plan will be valid up to August 14, 2023. As on February 13, 2023, the company had 682,659 shares within scope available for dividend and 2,341 shares in treasury through other repurchase. Buying Opportunity • Feb 10
Now 29% undervalued Over the last 90 days, the stock is up 11%. The fair value is estimated to be ₩188,436, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 10% over the last 3 years. Earnings per share has grown by 17%. Revenue is forecast to grow by 39% in 2 years. Earnings is forecast to grow by 39% in the next 2 years. Buying Opportunity • Dec 28
Now 20% undervalued Over the last 90 days, the stock is up 33%. The fair value is estimated to be ₩173,359, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 10% over the last 3 years. Earnings per share has grown by 17%. Revenue is forecast to grow by 37% in 2 years. Earnings is forecast to grow by 39% in the next 2 years. Valuation Update With 7 Day Price Move • Dec 09
Investor sentiment improved over the past week After last week's 16% share price gain to ₩130,000, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 21x in the Biotechs industry in South Korea. Total returns to shareholders of 3.3% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩173,421 per share. Annonce • Nov 25
Hugel's 'Letybo' First in Korea to Obtain Marketing Approval from Australia Hugel announced on November 24th, 2022 that they obtained marketing approval for 50 and 100 units of its botulinum toxin called 'Letybo' for the indication of glabellar lines from the Therapeutic Goods Administration (TGA) of Australia on the 23rd (local time). Australia is one of the top 10 countries for aesthetic procedures. Botulinum toxin accounts for the large proportion (41%) as a non-surgical aesthetic procedure, and the per capita treatment rate is known to be higher than that of the United States. The market size is estimated to be about KRW100bn as of 2022, and it is evaluated as a high potential market with annual growth of about 7% by 2025. Hugel plans to complete the first shipment and launch in the local market within the first quarter of 2023. The local subsidiary will be in charge of distribution and marketing. Hugel plans to implement aggressive sales and marketing activities to successfully settle into the Australian market and expand its market share. Moreover, in addition to reasonable pricing, Hugel plans to effectively deliver the efficacy and safety of Letybo by providing training for local medical staff and conducting academic programs in cooperation with major chain clinics and key opinion leaders. Board Change • Nov 16
Less than half of directors are independent There are 6 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 6 new directors. 1 experienced director. No highly experienced directors. 2 independent directors (5 non-independent directors). CEO & Executive Director Ji-hoon Sohn is the most experienced director on the board, commencing their role in 2018. Independent Director Patrick Holt was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. Major Estimate Revision • Aug 12
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 EPS estimate increased from ₩5,315 to ₩5,994. Revenue forecast steady at ₩285.2m. Net income forecast to grow 40% next year vs 7.7% growth forecast for Biotechs industry in South Korea. Consensus price target broadly unchanged at ₩182,571. Share price rose 5.7% to ₩134,200 over the past week. Valuation Update With 7 Day Price Move • Jul 13
Investor sentiment improved over the past week After last week's 17% share price gain to ₩124,000, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 28x in the Biotechs industry in South Korea. Negligible returns to shareholders over past three years. Price Target Changed • May 31
Price target decreased to ₩194,875 Down from ₩210,500, the current price target is an average from 8 analysts. New target price is 57% above last closing price of ₩124,400. Stock is down 38% over the past year. The company is forecast to post earnings per share of ₩5,318 for next year compared to ₩4,733 last year. Annonce • May 21
Hugel, Inc. Appoints Brent Saunders to its Board of Director Hugel, Inc. announced the appointment of Brent Saunders to its Board of Directors, effective immediately in advance of his election as Executive Chair on June 29, 2022. The news comes on the heels of the close of the Hugel Inc. transaction by a consortium led by CBC Group. Mr. Saunders brings Hugel over 25 years of expertise in the pharmaceutical and medical aesthetics industries and has facilitated over $300 billion in deals across the healthcare and life sciences sectors over the course of his career. Mr. Saunders previously served as Chairman, President, and CEO of Allergan Aesthetics until its 2020 acquisition by AbbVie in a transaction valued at approximately $63 billion. Allergan Aesthetics is the maker of Botox, the world's top-selling botulinum toxin brand, as well as the maker of leading dermal filler Judvederm. Earlier in his career, Mr. Saunders was President of Schering-Plough Corporation's Global Consumer Healthcare division, where he facilitated the company's acquisition of Organon Biosciences and the merger between Schering-Plough and Merck. Mr. Saunders also served as President and CEO of Forest Laboratories from 2013 to 2014, and Chairman and CEO of Bausch + Lomb Incorporated from 2010 to 2013. He currently serves as CEO of Vesper Healthcare Acquisition Corp. Board Change • Apr 27
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. No independent directors (7 non-independent directors). Non-Standing Director Hyunseung Kim was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Annonce • Apr 09
Hugel, Inc. (KOSDAQ:A145020) announces an Equity Buyback for KRW 50,000 million worth of its shares. Hugel, Inc. (KOSDAQ:A145020) announces a share repurchase program. Under the program, the company will repurchase up to KRW 50,000 million worth of its shares pursuant to a contract with Samsung Securities Co.,Ltd. The purpose of the buyback is to stabilize the share price and enhance the shareholder's value. The plan will be valid up to October 6, 2022. As on April 6, 2022, the company had 397,359 shares within scope available for dividend and 2,341 shares in treasury through other repurchase. Price Target Changed • Apr 07
Price target decreased to ₩214,889 Down from ₩231,333, the current price target is an average from 7 analysts. New target price is 93% above last closing price of ₩111,500. Stock is down 36% over the past year. The company is forecast to post earnings per share of ₩5,538 for next year compared to ₩4,733 last year. Valuation Update With 7 Day Price Move • Apr 04
Investor sentiment deteriorated over the past week After last week's 21% share price decline to ₩109,900, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 27x in the Biotechs industry in South Korea. Total loss to shareholders of 13% over the past three years. Price Target Changed • Feb 23
Price target decreased to ₩238,333 Down from ₩261,400, the current price target is an average from 7 analysts. New target price is 62% above last closing price of ₩146,700. Stock is down 16% over the past year. The company is forecast to post earnings per share of ₩5,229 for next year compared to ₩3,353 last year. Major Estimate Revision • Feb 15
Consensus EPS estimates fall by 10% The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from ₩307.6m to ₩287.4m. EPS estimate also fell from ₩6,781 per share to ₩6,085 per share. Net income forecast to grow 13% next year vs 9.3% growth forecast for Biotechs industry in South Korea. Consensus price target down from ₩261,400 to ₩247,000. Share price fell 3.5% to ₩141,800 over the past week. Valuation Update With 7 Day Price Move • Aug 30
Investor sentiment deteriorated over the past week After last week's 15% share price decline to ₩191,300, the stock trades at a forward P/E ratio of 28x. Average forward P/E is 28x in the Biotechs industry in South Korea. Total returns to shareholders of 32% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩240,156 per share. Valuation Update With 7 Day Price Move • Jun 09
Investor sentiment improved over the past week After last week's 21% share price gain to ₩243,000, the stock trades at a forward P/E ratio of 38x. Average forward P/E is 34x in the Biotechs industry in South Korea. Total returns to shareholders of 47% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩233,081 per share. Valuation Update With 7 Day Price Move • May 12
Investor sentiment improved over the past week After last week's 15% share price gain to ₩209,400, the stock trades at a forward P/E ratio of 36x. Average forward P/E is 34x in the Biotechs industry in South Korea. Total returns to shareholders of 31% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩178,730 per share. Is New 90 Day High Low • Feb 24
New 90-day low: ₩174,400 The company is down 12% from its price of ₩198,300 on 26 November 2020. The South Korean market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₩108,457 per share. Annonce • Feb 11
Hugel, Inc. Announces Approval to Launch of Letybo 50U in Prc Market Sihuan Pharmaceutical Holdings Group Ltd. announced that Letybo® 50U a product exclusively distributed by the Company and produced by a Hugel, Inc., has been officially approved for launch in the market by the National Medical Products Administration of the People's Republic of China on 10 February 2021, and which will together with the Letybo® 100U previously approved for launch on 21 October 2020, to provide users in the PRC with shape beauty options. Letybo® is the fourth type A botulinum toxin approved for launch in the market of the PRC and the first of its kind in Korea. Letybo® was developed by Hugel and commands the large market share among the botulinum toxin products in Korea. Since the launch of its botulinum toxin products in Korea in 2010, Hugel has become the first Korean biopharmaceutical company among the four companies which have obtained approval to launch botulinum toxin products in the PRC market. As for product quality, Hugel uses patented technology to completely extract high-purity compound protein and adopts stricter quality control than the Ministry of Food and Drug Safety of Korea to ensure quality throughout the entire production process which is protected by patents. Hugel insists on high quality, high standards and high efficiency. According to market feedback, the per capita effective dose equivalent is 50U, which will be the mainstream in the market in the future. Leveraging the accurate effects and appropriate therapeutic dose, Letybo® 50U satisfies the customers' needs for higher cost performance in term of product type and complies with the project management, operation and development value of hospital institutions. Letybo® 50U enriches the specifications and types of products based on the fact that Letybo® 100U has been approved for marketing in the market of China, which is benefit to the market popularization of normal Letybo® products. It is expected that the sales of botulinum toxin products in China will surge in the coming five years and sales will reach USD 1.8 billion (approximately HKD 13.5 billion) in 2025, making China one of the three major global markets alongside with the United States and the European Union. The Group's goal is to shape Letybo into the No. 1 botulinum toxin brand in China and to achieve a market share of over 30% in China within three years. With regard to the sales layout of Letybo, the Company has commenced preliminary works so as to fully prepare for the official launch of Letybo within this year. Relying on the Group's sales network in more than 200 cities in China and the use of mature and efficient sales promotion methods and models, the sales performance of Letybo is highly expected. Currently, the Group has strategically established a sales model in which direct sales and agent teams cooperate with each other, and has established a strong and experienced professional sales team. At the beginning of 2021, there were more than 3,000 cooperative institutions. In addition, the Company will fully consider the characteristics, similarities and differences of various markets in China, and focus on Beijing, Shanghai, Guangzhou, Shenzhen and other first-tier cities with huge population bases, high spending power, and huge demand for medical aesthetics. Also, the Company will consolidate academic research in association with Hugel Expert Leader's Forum, a leading symposium widely respected across the medical aesthetics industry in Korea, to lay a more solid foundation for Letybo's brand awareness. The market highly values the Group's medical aesthetics platform and its core products, namely hyaluronic acid and botulinum toxin. The introduction of Letybo into the Group's medical aesthetics platform will not only enrich and expand the platform's product portfolio, but also reflect the Group's product layout strategy towards diversification and internationalization. The Group expects to expand the market awareness of its products and brands through the implementation of marketing projects and reasonable pricing. The Group will deepen communication with medical institutions and doctor groups to further improve service standards and expand market share. The Group will also develop its ability to compete against its peers so as to outrun its competitors and to become the leading and first-class medical aesthetics platform. Annonce • Feb 10
Hugel, Inc., Annual General Meeting, Mar 26, 2021 Hugel, Inc., Annual General Meeting, Mar 26, 2021, at 09:00 Korea Standard Time. Annonce • Feb 03
Hugel, Inc. to Report Fiscal Year 2020 Results on Feb 09, 2021 Hugel, Inc. announced that they will report fiscal year 2020 results on Feb 09, 2021 Valuation Update With 7 Day Price Move • Jan 19
Investor sentiment improved over the past week After last week's 15% share price gain to ₩226,500, the stock is trading at a trailing P/E ratio of 71.4x, up from the previous P/E ratio of 62x. This compares to an average P/E of 62x in the Biotechs industry in South Korea. Total returns to shareholders over the past three years are 13%. Is New 90 Day High Low • Jan 18
New 90-day high: ₩224,700 The company is up 20% from its price of ₩187,200 on 20 October 2020. The South Korean market is up 30% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is up 19% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₩154,133 per share. Price Target Changed • Jan 10
Price target raised to ₩251,818 Up from ₩233,969, the current price target is an average from 10 analysts. The new target price is 27% above the current share price of ₩198,000. As of last close, the stock is up 49% over the past year.